



Supplemental Figure 1: Treatment summaries and molecular findings in patients with AR-inhibitor therapy and AR-V7

A. MSK-fusion results were available for both the pre-AR inhibitor treatment primary tumor and post-AR inhibitor treatment metastasis. The primary (1: breast biopsy; 2: breast excision) and metastatic (3) tumors are clonally related. AR-V7 was not identified in the pre-treatment primary tumor but was identified in the post-treatment bone metastasis. **B.** MSK-fusion results were available for the primary (1: breast excision) and metastatic (2) tumors prior to AR inhibitor treatment. Both samples showed an ATG7-RAF1 in-frame fusion but AR-V7 was only identified in the metastatic tumor.